Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 5 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
6(100.0%)
6Total
Phase 1(6)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT06798519Phase 1Not Yet Recruiting

Relative Bioavailability Study of HNC364 Injectable Suspension

Role: lead

NCT05523570Phase 1Completed

A Study to Evaluate the Safety, Tolerability, PK and PD of HNC364 Injectable Suspension

Role: lead

NCT05803850Phase 1Completed

A Study to Evaluate the Safety, Tolerability, PK and PD of HNC1058

Role: lead

NCT04603989Phase 1Completed

A Study of HNC042 in Healthy Chinese Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics

Role: lead

NCT04504448Phase 1Completed

A Study of HNC664 in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics

Role: lead

NCT03740555Phase 1Completed

A Study of HNC042 in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics.

Role: lead

All 6 trials loaded